drugset / Trial / NCT07283822
Amping up With PemJAK
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Timeline
- Start
- 2025-12-03
- Primary completion
- 2028-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |